Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected to Post Quarterly Sales of $1.81 Million

Equities analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to announce sales of $1.81 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Eiger BioPharmaceuticals’ earnings, with estimates ranging from $1.07 million to $2.54 million. The business is expected to announce its next earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full year sales of $9.37 million for the current fiscal year, with estimates ranging from $8.20 million to $10.54 million. For the next fiscal year, analysts forecast that the firm will post sales of $12.68 million, with estimates ranging from $12.29 million to $13.07 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Thursday, August 5th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03).

A number of equities research analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Eiger BioPharmaceuticals from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 9th. Zacks Investment Research lowered shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 10th. Finally, BTIG Research restated a “buy” rating and issued a $45.00 price objective on shares of Eiger BioPharmaceuticals in a report on Friday, August 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $26.17.

Shares of EIGR traded down $0.18 during mid-day trading on Monday, reaching $7.03. The company’s stock had a trading volume of 192,153 shares, compared to its average volume of 213,024. The stock has a market cap of $238.68 million, a PE ratio of -8.79 and a beta of 1.34. The company has a current ratio of 7.48, a quick ratio of 7.35 and a debt-to-equity ratio of 0.29. Eiger BioPharmaceuticals has a 52 week low of $6.80 and a 52 week high of $13.49. The company’s fifty day moving average price is $8.01 and its two-hundred day moving average price is $8.37.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in shares of Eiger BioPharmaceuticals by 52.2% in the first quarter. Dimensional Fund Advisors LP now owns 164,740 shares of the biotechnology company’s stock worth $1,456,000 after buying an additional 56,530 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Eiger BioPharmaceuticals by 13.5% in the first quarter. Ameriprise Financial Inc. now owns 4,450,241 shares of the biotechnology company’s stock worth $39,376,000 after buying an additional 528,406 shares during the period. Weiss Multi Strategy Advisers LLC increased its stake in shares of Eiger BioPharmaceuticals by 1.2% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 200,000 shares of the biotechnology company’s stock worth $1,770,000 after buying an additional 2,453 shares during the period. Trellus Management Company LLC increased its position in Eiger BioPharmaceuticals by 8.0% during the 2nd quarter. Trellus Management Company LLC now owns 244,081 shares of the biotechnology company’s stock valued at $2,080,000 after purchasing an additional 18,081 shares during the period. Finally, GSA Capital Partners LLP increased its position in Eiger BioPharmaceuticals by 200.7% during the 2nd quarter. GSA Capital Partners LLP now owns 79,912 shares of the biotechnology company’s stock valued at $681,000 after purchasing an additional 53,337 shares during the period. 68.68% of the stock is currently owned by institutional investors.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Read More: Equity Income

Get a free copy of the Zacks research report on Eiger BioPharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.